Table 3 Vasorelaxant activity (EC50, µM and emax, %) of the tested compounds.

From: Synthesis of potent vasodilating agents: in silico and in vitro evaluation of 6-(4-substitutedphenyl)-3-pyridazinone derivatives as potential hydralazine analogues

Compound no.

EC50 (µM)a

Emax ± SD (%)

Compound no.

EC50 (µM)a

Emax ± SD (%)

2a

0.42 ± 0.02

90.94 ± 0.70

2f

1.899 ± 0.003271

93.70 ± 0.28

2b

0.22 ± 0.01

91.24 ± 0.24

2g

0.2180 ± 0.001581

96.98 ± 0.32

2c

0.26 ± 0.006

97.18 ± 0.59

2h

0.07154 ± 0.00113

99.81 ± 0.73

2d

0.19 ± 0.004

97.51 ± 0.43

2i

1.907 ± 0.00507

98.26 ± 0.27

2e

0.11 ± 0.003

95.79 ± 0.24

2j

0.02916 ± 0.0002702

99.74 ± 0.19

Hydralazine

18.21b

-

Diazoxide

19.5b

-

Isosorbide mononitrate

30.10b

-

Nitroglycerin

0.1824 ± 0.005983

95.58 ± 1.96

  1. a EC50: Effective drug concentration causing 50% relaxation of the phenylephrine contraction of rat aorta rings. b According to the reported results10,20,21
  2. *Value represents the mean ± SD, n = 5.
Back to article page